Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
594 Leser
Artikel bewerten:
(2)

BMO Financial Group: BMO Announces Retirement of Patrick Cronin, Names Piyush Agrawal Chief Risk Officer

Finanznachrichten News

TORONTO, June 8, 2022 /PRNewswire/ -- Bank of Montreal (TSX:BMO) (NYSE:BMO) today announced the upcoming retirement of its Chief Risk Officer, Patrick Cronin, and the appointment of Piyush Agrawal into the role. Mr. Agrawal will join the bank as Deputy Chief Risk Officer on July 1 and, after a transition period with Mr. Cronin, become Chief Risk Officer on November 1.

Piyush Agrawal

Mr. Agrawal, a seasoned executive with global risk experience, joins BMO from Citigroup, where he held the role of Chief Risk Officer for Citibank, N.A. and Global Head of Climate Risk since 2021. He joined Citigroup in 2002, holding roles including Chief Operating Officer of Citibank N.A., Chief Risk Officer of Asia Pacific, and Head of Corporate Strategy.

"I'm delighted to welcome Piyush to BMO, and we are excited to have him join our leading risk management group," said Darryl White, Chief Executive Officer, BMO Financial Group. "I have been particularly impressed by his business acumen, customer focus, regulatory experience, along with his deep risk management capabilities and expertise on ESG and climate topics. His reputation for personal curiosity and lifelong learning, as well as developing high performing teams, precedes him. These behaviours are essential to a strong risk function and are at the core of BMO's culture."

Mr. Cronin first joined BMO in 1993, holding important leadership roles in BMO Capital Markets including Head of Trading Products, Chief Operating Officer, and CEO & Group Head, before his appointment as Chief Risk Officer of BMO Financial Group in 2018. Mr. Cronin has also served as an Advisory Board member of Western University'sIvey School of Business, as well as on the board of the Loran Scholars Foundation. He is past Sector Chair of the United Way Toronto & York Region Individual Giving Cabinet, as well as BMO's own Employee Giving campaign.

"Throughout his career, Pat has made a significant impact across our bank," continued Mr. White. "He expertly steered our COVID-19 response and our Risk function through the pandemic and the complex credit and market environment that has defined the past 24 months. He is a trusted advisor, and one of the strongest bankers I have worked with. He has also shown a true commitment to the communities we serve, helping to Grow the Good for so many. I consider it a privilege to have delivered for our stakeholders alongside him for decades."

About BMO Financial Group
Serving customers for 200 years and counting, BMO is a highly diversified financial services provider - the 8th largest bank, by assets, in North America. With total assets of $1.04 trillion as of April 30, 2022, and a team of diverse and highly engaged employees, BMO provides a broad range of personal and commercial banking, wealth management and investment banking products and services to more than 12 million customers and conducts business through three operating groups: Personal and Commercial Banking, BMO Wealth Management and BMO Capital Markets.

Internet: www.bmo.com | Twitter: @BMOMedia

For News Media Inquiries: Paul Gammal, Toronto, paul.gammal@bmo.com, (416) 867-3996

Photo - https://mma.prnewswire.com/media/1834920/BMO_Financial_Group_BMO_Announces_Retirement_of_Patrick_Cronin_.jpg

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.